FireCyte Therapeutics
FireCyte is developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye
Valitor
Biopolymers to Engineer Superior Biopharmaceuticals
Valitor is developing a pipeline of biopharmaceuticals using a proprietary platform technology that originated at UC Berkeley. Their products are designed to achieve previously unattainable pharmacological properties, thereby overcoming key challenges for major market indications. By leveraging established clinical mechanisms of action, Valitor can substantially de-risk the development of best-in-class therapies.
Their lead product is a long-acting anti-VEGF therapy for exudative retinal diseases, which meets a challenging and unmet clinical requirement for improving efficacy. In addition to products for ophthalmology, Valitor is also developing products in two additional pipeline areas: immuno-oncology and inflammatory joint diseases.